Gilead Sciences
-
{
- All
- News
- Videos
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
How to Fix a Broken Market in Antibiotics
When sophisticated bugs that medicines used to kill within days start to fight back and win, all of healthcare and the people it keeps alive are in trouble.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
A Blue Pill Is Stopping HIV, World-First Study Shows
New cases of HIV among gay and bisexual men fell by almost a third, according to a study to measure the impact of Gilead’s pill.
-
Gilead to Sell Cheaper Versions of Drug That Sparked Cost Debate
Gilead’s new drugs will be sold through a new subsidiary called Asegua Therapeutics.
-
Drugmakers Cancel Price Hikes After California Law Takes Effect
The California law is a way of publicly pressuring pharmaceutical companies to keep prices down.
-
How a Blue Pill Is Stopping HIV From Sydney to San Francisco
Gilead’s Truvada is preventing HIV and has helped drive cases to the lowest since 1985.
-
Big Pharma Dominates Ranking Of Stocks With Best 5-year Returns
U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.
-
Gilead Sciences Keen to Set Up Manufacturing Unit in Hyderabad
US-based Gilead Sciences, a research-based company, has evinced interest in setting up a manufacturing unit in the proposed 'Pharma City' near here.
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
How to Fix a Broken Market in Antibiotics
When sophisticated bugs that medicines used to kill within days start to fight back and win, all of healthcare and the people it keeps alive are in trouble.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
A Blue Pill Is Stopping HIV, World-First Study Shows
New cases of HIV among gay and bisexual men fell by almost a third, according to a study to measure the impact of Gilead’s pill.
-
Gilead to Sell Cheaper Versions of Drug That Sparked Cost Debate
Gilead’s new drugs will be sold through a new subsidiary called Asegua Therapeutics.
-
Drugmakers Cancel Price Hikes After California Law Takes Effect
The California law is a way of publicly pressuring pharmaceutical companies to keep prices down.
-
How a Blue Pill Is Stopping HIV From Sydney to San Francisco
Gilead’s Truvada is preventing HIV and has helped drive cases to the lowest since 1985.
-
Big Pharma Dominates Ranking Of Stocks With Best 5-year Returns
U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.
-
Gilead Sciences Keen to Set Up Manufacturing Unit in Hyderabad
US-based Gilead Sciences, a research-based company, has evinced interest in setting up a manufacturing unit in the proposed 'Pharma City' near here.
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
